Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has recruited the first patient for its Phase 2B MDMA-assisted therapy trial for post-traumatic stress disorder (PTSD). The EMDMA-001 trial has been designed to assess the safety, efficacy and cost-effectiveness of MDMA-assisted therapy for PTSD. It aims to generate vital data that will strengthen Emyria's position as a leader in providing psychedelic-assisted therapy within a comprehensive multidisciplinary clinical service.
Emyria recruits first patient for MDMA-assisted therapy trial
